FDA's Approval Trends for Peptide Drugs Over the Past Three Years: Accelerating Peptide NDA Approvals

2026-05-12

According to Kelly's 2024 review in the Journal of Peptide Science, the number of peptide drugs approved by the FDA has been on the rise, with the average approval time for NDAs from 2019 to 2022 shortened by 30%.

In recent years, peptide drugs have attracted attention in the pharmaceutical R&D field due to their unique therapeutic potential and relatively low side effects. FDA approval data shows an upward trend in the number of new drug applications (NDA) for peptide drugs from 2019 to 2022, as clearly demonstrated in Kelly's 2024 review published in the Journal of Peptide Science. The review analyzed the FDA's approval trends and pointed out that compared to three years ago, the average approval time for FDA's NDA has been shortened by 30%, indicating optimization in the FDA's approval process and advancements in technical assessments in the field of peptide drugs. This change implies that peptide drugs can enter the market more quickly, offering new treatment options for patients. With the development of peptide synthesis and analytical technologies, it is expected that the FDA's peptide NDA approval process will continue to be optimized in the coming years, further accelerating the development and market launch of peptide drugs.